Overall, our in vivo studies depleting CD4+ T cells and employing the CXCR3-blocking Ab highlight infiltration of CXCR3-expressing T cells as a potential mechanism that contributes to tumor regression in the context of this combination therapy. This evidence concerns the gene CD4 and neoplasm.